Beyond GLP-1s: Inside Obesity’s $80 Billion Second Wave
The first wave of obesity innovation proved a simple point: meaningful weight loss can be delivered at scale if patients can start therapy, stay on it, and afford it. GLP-1s turned obesity into one of ...
ESMO 2026 Preview: What the Abstracts Reveal Before the Data Drops
Every major oncology congress has its headline moments: a trial that changes practice, a therapy that exceeds expectations, or a new mechanism that suddenly becomes the industry's next big focus.But E ...
How Patient Journey Analytics Improves Drug Commercialization
A drug's clinical trial data tells you how it performs under ideal conditions. It doesn't tell you where your patients actually are, why they're taking three years to get diagnosed, which physicians a ...
Clinical Differentiation Is No Longer Enough: How “Access Differentiation” Is Becoming the Real Moat
A therapy can post best-in-class trial data and still stall at launch. Not because the science was wrong, but because nobody could tell a payer what happens after the trial ends, when the drug meets r ...
Can Premium Pricing Survive in Rare Diseases? What 2026 Signals Say
For nearly two decades, rare diseases have lived in a pricing exception zone. Small patient populations, high unmet need, limited competition, and outcomes that could genuinely change a patient's life ...